Literature DB >> 19444974

The outcome of cementless total hip arthroplasty in haemophilic hip arthropathy.

M C Yoo1, Y J Cho, K I Kim, A Ramteke, Y S Chun.   

Abstract

Total hip arthroplasty (THA) in haemophilic arthropathy is reported to be less successful than in non-haemophilic indications. Although preliminary results are encouraging, the survival and functional outcome of cementless THA in haemophilia are not known. The aim of this study was to analyse mid-term results of cementless THA in haemophilia. Twenty-seven consecutive cementless THAs with 23 patients performed between June 1995 and June 2003 were reviewed. Mean age at time of operation was 36 years and mean follow-up period was 92 months (range, 60-156). Radiographic assessment was done for fixation of components, loosening, osteolysis, wear and bone responses around the implants. The factor requirements, amount of transfusion and complications associated with bleeding were studied. The mean preoperative Harris hip score changed from 57 to 95.9 at the latest follow-up. The survival at mean follow-up was 95.2%. One patient with osteolysis around acetabular cup was re-operated with bone-grafting and change of polyethylene liner. One loose cup was revised with a cemented cup. All other components were deemed stable at the latest follow-up. A standardized management protocol and dedicated team approach comprising of haematologist, physicians, physical therapist, nurses and coordinators is needed for excellent results. The present retrospective study shows that the functional results of cementless THA in haemophilia are satisfactory as it happens in osteoarthritic patients according to the current literature, mainly the younger. Thus, taking into account that the majority of haemophilia patients requiring a THA are relatively young, cementless THA is currently recommended.

Entities:  

Mesh:

Year:  2009        PMID: 19444974     DOI: 10.1111/j.1365-2516.2009.01986.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  7 in total

1.  Total Hip Arthroplasty in Hemophilia Patients: A Mid-term to Long-term Follow-up.

Authors:  Guo-Liang Wu; Ji-Liang Zhai; Bin Feng; Yan-Yan Bian; Chi Xu; Xi-Sheng Weng
Journal:  Orthop Surg       Date:  2017-11       Impact factor: 2.071

2.  Total hip arthroplasty in patients with haemophilia - What are the risks of bleeding in the immediate peri-operative period?

Authors:  Grainne Colgan; Joseph F Baker; N Donlon; N Hogan; T McCarthy
Journal:  J Orthop       Date:  2016-07-27

3.  Comparison of metal on metal versus polyethylene-ceramic bearing in uncemented total hip arthroplasty in patients with haemophilic arthropathy.

Authors:  Joannis Panotopoulos; Cihan Ay; Reinhard Schuh; Stephan Domayer; Philipp Funovics; Klemens Trieb; Hugo Wanivenhaus; Reinhard Windhager
Journal:  Int Orthop       Date:  2014-04-12       Impact factor: 3.075

4.  Perioperative management of hemophilia patients receiving total hip and knee arthroplasty: a complication report of two cases.

Authors:  Toshiyuki Tateiwa; Yasuhito Takahashi; Tsunehito Ishida; Kosuke Kubo; Toshinori Masaoka; Takaaki Shishido; Keiji Sano; Kengo Yamamoto
Journal:  Ther Clin Risk Manag       Date:  2015-09-15       Impact factor: 2.423

5.  Comparison of continuous infusion versus bolus injection of factor concentrates for blood management after total knee arthroplasty in patients with hemophilia.

Authors:  Young Shil Park; Won-Ju Shin; Kang-Il Kim
Journal:  BMC Musculoskelet Disord       Date:  2017-08-22       Impact factor: 2.362

6.  Total hip arthroplasty via the direct anterior approach with Kerboull-type acetabular reinforcement device for an elderly female with factor XI deficiency.

Authors:  Kei Sano; Yasuhiro Homma; Tomonori Baba; Jun Ando; Mikio Matsumoto; Hideo Kobayashi; Takahito Yuasa; Kazuo Kaneko
Journal:  SICOT J       Date:  2017-02-13

Review 7.  Interplay Between Iron Overload and Osteoarthritis: Clinical Significance and Cellular Mechanisms.

Authors:  Chenhui Cai; Wenhui Hu; Tongwei Chu
Journal:  Front Cell Dev Biol       Date:  2022-01-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.